Evidence map›Paper›PMID 40546642›Full record

ArticleCureus2025

Low Secretory Leukocyte Protease Inhibitor (SLPI)-Level Potentiates Alternaria Extract-Induced T-Helper 2 (Th2) Airway Inflammation via the Interleukin-33 (IL-33) Pathway.

Taizo Hirano, Akira Koarai, Shinya Ohkouchi, Hisatoshi Sugiura, Hajime Kurosawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Taizo HiranoDepartment of Occupational Health, Graduate School of Medical Sciences, Tohoku University Graduate School of Medicine, Sendai, JPN.
Akira KoaraiDepartment of Respiratory Medicine, Sendai City Hospital, Sendai, JPN.
Shinya OhkouchiDepartment of Occupational Health, Graduate School of Medical Sciences, Tohoku University Graduate School of Medicine, Sendai, JPN.
Hisatoshi SugiuraDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Tohoku University Graduate School of Medicine, Sendai, JPN.
Hajime KurosawaDepartment of Occupational Health, Graduate School of Medical Sciences, Tohoku University Graduate School of Medicine, Sendai, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Serine proteases play a critical role in the augmented release and cleavage of IL-33, leading to the expansion of group 2 innate lymphoid cells (ILC2s) and T-helper 2 (Th2) airway inflammation. However, the protective regulation of protease-dependent interleukin-33 (IL-33) activation remains poorly understood. Therefore, we investigated the role of secretory leukocyte protease inhibitor (SLPI), as a serine protease inhibitor, in this protective regulation and aimed to clarify its contribution to type 2 immunity. Methods We evaluated the role of SLPI in the

Indexed as

asthmail-33secretory leukocyte protease inhibitor (slpi)serine proteasetype 2 innate lymphoid cells (ilc2s)

Identifiers

PMID40546642
PMCPMC12180379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.